Project Grant HT94252411060
Award Date
11/1/24
Completion Date
10/31/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award of $546,000.00 from the Defense Health Agency supports research at the Regents of the University of Michigan to develop a novel lectin for targeting T-cell lymphomas. The award is part of the Military Medical Research and Development program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for service members and the public through innovative and impactful research. The 3-year award began on September 1, 2023 and will...
The Defense Health Agency awarded a $607,377 Project Grant to the Regents of the University of Michigan to fund a 2-year research project titled "A NEW IDEA FOR ADVANCING AXITINIB-BASED THERAPY IN RECURRENT AND METASTATIC HNSCC." This grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. The University of Michigan, a leading...
This federal Project Grant award, valued at $1,100,747.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to engineer antibody-drug conjugates that can coordinate the innate and adaptive immune systems for curative responses. The primary awardee is the Regents of the University of Michigan, a prominent U.S. state government-owned educational institution with extensive expertise in federal research and...
The University of Michigan will receive $1.2 million from the Defense Health Agency under a three-year Project Grant award for research titled "FADD: A Mechanistic Basis and Therapeutic Opportunity for Overcoming CDK4/6 Inhibitor Resistance." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...
The University of Michigan received a $925,834 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research into CDK12 as a context-specific tumorigenesis regulator and novel therapeutic target in castration-resistant prostate cancer. The research will be performed in Ann Arbor, Michigan over a three-year period from September 2021 through August 2024. Through the support of basic,...
The Regents of the University of Michigan received a $312,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 2-year grant, awarded on February 1, 2024, supports research to investigate "An Unexpected Role for the Ubiquitin Proteasome System in Repeat Associated Non-AUG Translation." This basic and translational biomedical research aims to advance understanding and treatment of neurological disorders...
The Defense Health Agency awarded a $1,178,939.00 Project Grant to the Regents of the University of Michigan under the Military Medical Research and Development program (CFDA 12.420) to conduct advanced phenotyping research to improve diagnostic, longitudinal assessment, and treatment strategies for deployment-related respiratory disease. The award period is from September 1, 2023 to August 31, 2026. As a U.S. Government Entity and top public research university, the University of Michigan has...
This Cooperative Agreement award of $1,248,000.00 from the Defense Health Agency supports Phase 1/2 clinical trials assessment of kidney cancer therapeutics at the University of Michigan under the Military Medical Research and Development (CFDA 12.420) program. The project, titled "University of Michigan Phase 1/2 Clinical Trials Assessment in Kidney Cancer Therapeutics (U-MPAKT)," will focus on advancing innovative medical solutions for the treatment of kidney cancer, which is a...
The University of Michigan will receive $546,000 from the Department of the Army Medical Command under a Project Grant award to model virus-associated Merkel cell carcinoma in mice using viral DNA regulatory sequences from September 1, 2022 to August 31, 2025. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...